Magnolia Medical Technologies is on a Mission to ZERO®. Today, we offer healthcare institutions a solution to some of their biggest hidden problems – contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy, and false-positive CLABSIs. Tomorrow, we aspire to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike.
We know that setting new standards of care is a journey enabled by purposeful innovation, partnerships, and perseverance. As the first step of our journey, we have successfully developed and proven our evidence-based technology platform, Steripath, which we’ve coupled with unparalleled support to change clinical practices and prevent unnecessary patient harm as well as system-wide costs associated with the misdiagnosis of sepsis.
Our mission is further enabled by reducing false-positive CLABSIs and leveraging our extensive intellectual property portfolio – consisting of over 100 issued method, apparatus, and design patents and 70+ patent applications pending – to address other important sources of diagnostic error that are harmful to patients and costly to hospitals.
-
Industry
-
Medical Equipment Manufacturing
-
Company size
-
51-200 employees
-
Headquarters
-
Seattle, Washington
-
Type
-
Privately Held
-
Founded
-
2006
-
Specialties
-
Healthcare, Hospital, Emergency Departments, Antimicrobial Stewardship, Nursing, Medical Reimbursement, Sepsis Prevention, Accurate Blood Testing, Medical Devices, Hospital Reimbursement, Hospital, Medical Technology, Healthcare Technology, Blood Culture Collection, and Infectious Disease Prevention